Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.
In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies Congress-VIRTUAL, we would be focusing on the manufacturing, process development, regulatory aspects of cell therapies and gene therapies. The special impact would be laid on, gene delivery based therapies, car-T cell-based immunotherapies, automated manufacturing, allogenic therapies, with the aspects of hurdles in supply chain management and regulatory affairs.
Click here to view the post show report for the 2nd Annual MarketsandMarkets Cell-Gene therapy Bioprocessing Online Conference
, Leiden University Medical Centre
Technical Director, Wyatt Technology, UK
CSO and Co-founder, Atelerix Ltd
Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing, Aston University
Bioprocess development & facility design, Werum IT Solutions
Protein Sales Manager, Proteintech Group
European Applications Manager, Nova Biomedical
Founder & CEO, Adva Biotechnology
VP Product Development, Boyd Consultants Ltd
Director of Operations & Business Development, Anemocyte
Acting Head, Division of Advanced Therapies Director, UK Stem Cell Bank